SecBot SecBot
SECBOTREPLAY Home › Report › TLX

TLX · Telix reported a strong H1 2026 with revenue of $477.4M (+22% YoY),…

Telix Pharmaceuticals Ltd · 6-K filed Aug 19, 2026 at 21:48 ET

At the news

BULLISHIMPACT 7/10

6-K filed Aug 19, 2026 at 21:48 ET

Telix reported a strong H1 2026 with revenue of $477.4M (+22% YoY), swinging to a net profit of $38.3M from a -$2.3M loss, driven by Precision Medicine growth ($388.6M, +27%) and a $40M Regeneron collaboration payment. The company raised FY 2026 revenue guidance to the upper end of $950M-$970M range and increased R&D investment 52% to $123.8M. Key catalysts include a PDUFA date of September 11, 2026 for Pixclara (TLX101-Px) and progress across multiple late-stage therapeutic programs.

  • Revenue from contracts with customers was $477.4M for H1 2026, up 22% from $390.4M in H1 2025.
  • Net profit after tax was $38.3M, compared to a loss of $2.3M in H1 2025.
  • Precision Medicine segment revenue grew 27% to $388.6M, with gross margin improving to 65%.
  • Adjusted EBITDA was $51.9M, up 148% from $21.1M in H1 2025.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access